ArticleInfection and drug resistance2023
Risk Factors and Outcomes of Patients with Carbapenem-Resistant
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characteristics and risk factor analysis of carbapenem-non-susceptible Pseudomonas aeruginosa causing bacteremia in a tertiary hospital (2014-2023).BMC microbiology · 2026Article
- Heterotrophic fermentation of a robust human defensin in Chlamydomonas reinhardtii provides a stable and potent antibacterial.Microbial cell factories · 2026Article
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Temporal Trends in Antimicrobial Resistance in a Tertiary Hospital in Western Guangxi, China: A Five-Year Surveillance Study (2021-2025).Infection and drug resistance · 2026Article
- Whole-genome sequencing reveals resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa bloodstream infections.BMC microbiology · 2025Article
- Prevalence of multidrug resistant gram-negative bacteria and associated factors among gram-negative blood culture isolates at Tikur Anbessa Specialized Hospital: a retrospective study.BMC infectious diseases · 2025Article
- Article
- Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China.Scientific reports · 2025Article
- Predicting carbapenem-resistant Pseudomonas aeruginosa infection risk using XGBoost model and explainability.Scientific reports · 2025Article
- Ceftazidime-avibactam use in hematology patients: single-center experience.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Article
- Difficult-to-TreatAntibiotics (Basel, Switzerland) · 2025Review
- Risk Factors for Development and Mortality of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.Infection · 2024Review
- The Prevalence of Metallo-Beta-Lactamese-(MβL)-ProducingMicroorganisms · 2023Review
- Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-ResistantInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The rising incidence of carbapenem-resistant Methods: We performed a retrospective cohort study of patients with PA-BSI in a tertiary hospital from January 2017 to December 2021 in China. Epidemiological, clinical, and microbiological characteristics were described. Risk factors for CRPA-BSI and the outcomes of PA-BSI inpatients were identified, using multivariate logistic regression analysis. Results: A total of 198 PA-BSI inpatients were included. The negative outcome rate was significantly higher in patients infected with CRPA (15/34, 44.12%) than with carbapenem-susceptible Conclusion: Our study showed that previous exposure to carbapenem was an independent risk factor for CRPA-BSI. CRPA was not an independent risk factor for a negative outcome in PA-BSI inpatients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.